Processing

Please wait...

Settings

Settings

1. WO2000040741 - LENTIVIRUS VECTOR SYSTEM

Publication Number WO/2000/040741
Publication Date 13.07.2000
International Application No. PCT/US2000/000390
International Filing Date 06.01.2000
Chapter 2 Demand Filed 31.07.2000
IPC
C12N 15/867 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
867Retroviral vectors
CPC
C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
C12N 2740/15043
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
15011Lentivirus, not HIV, e.g. FIV, SIV
15041Use of virus, viral particle or viral elements as a vector
15043viral genome or elements thereof as genetic vector
C12N 2740/15052
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
15011Lentivirus, not HIV, e.g. FIV, SIV
15051Methods of production or purification of viral material
15052relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/16043
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16041Use of virus, viral particle or viral elements as a vector
16043viral genome or elements thereof as genetic vector
C12N 2740/16052
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16051Methods of production or purification of viral material
16052relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2840/203
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2840Vectors comprising a special translation-regulating system
20translation of more than one cistron
203having an IRES
Applicants
  • THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer 6011 Executive Boulevard Suite #325 Rockville, MD 20852, US (AllExceptUS)
  • ARYA, Suresh, K. [US/US]; US (UsOnly)
Inventors
  • ARYA, Suresh, K.; US
Agents
  • NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP. One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, OR 97204, US
Priority Data
60/115,24707.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) LENTIVIRUS VECTOR SYSTEM
(FR) SYSTEME DE VECTEURS LENTIVIRAUX
Abstract
(EN)
A method is disclosed for improving encapsidation of transgene RNA using retroviral packaging and transfer vectors. An HIV-2 transfer vector, which includes the transgene, is introduced into a packaging cell that is also transfected with (or stably expresses) an HIV-2 derived packaging vector or a combination of packaging vectors. The packaging vector has mutations in packaging signal sequences that are both upstream and downstream of the 5' splice donor site. It can also be composed of a combination of two or more partial vectors. A transfer vector, which is introduced into the packaging cell line, has a mutation that renders its splice donor site non-functional. Transgene RNA expression and encapsidation from these cells is markedly increased, but with little or no levels of infectious viral RNA encapsidation.
(FR)
Cette invention concerne un procédé permettant l'amélioration de l'encapsidation d'ARN transgénique au moyen de vecteurs d'encapsidation rétrovirale et de transfert. On introduit un vecteur de transfert VIH-2, comprenant le transgène, à l'intérieur d'une cellule d'encapsidation, qui est également transfectée avec un vecteur d'encapsidation dérivé du VIH-2 ou une combinaison de vecteurs d'encapsidation, ou qui exprime de manière stable ledit vecteur ou ladite combinaison. Le vecteur d'encapsidation possède des mutations dans les séquences de signal d'encapsidation, situées à la fois en amont et en aval du site donneur d'épissure 5'. Il peut également être composé d'une combinaison de deux ou plusieurs vecteurs partiels. Un vecteur de transfert, que l'on introduit dans la lignée de cellules d'encapsidation, possède une mutation qui rend son site donneur d'épissure non fonctionnel. L'expression de l'ARN transgénique et l'encapsidation par ces cellules sont nettement augmentées, mais avec des taux faibles voire nuls d'encapsidation d'ARN viral infectieux.
Latest bibliographic data on file with the International Bureau